title: Delay of radiation-induced decline and recovery of hematopoiesis following treatment with anti-HLA-DR antibody.
abstract: A dose of 200 cGy of total-body irradiation (TBI) is nonlethal in dogs: Following a granulocyte nadir in the third week post-TBI, peripheral blood cell counts recover to normal values by about 5 weeks. In the context of studies on a potential role of major histocompatibility (MHC) class II antigens in the regulation of stress hematopoiesis, we tested the effect of anti-MHC class II monoclonal antibodies (mAbs) on hematologic recovery after TBI. Thirteen dogs were given 200 cGy of TBI not followed by marrow infusion. Five received no additional treatment (concurrent controls) and eight were given daily intravenous (IV) injections of anti-class II mAbs H81.9 (anti-HLA-DR; n = 6) or B1F6 (anti-HLA-DR and -DP; n = 2) at 0.6 (n = 4) or 1.2 mg/kg/d (n = 4) on days 0-4 (n = 7) or days 0-9 (n = 1). One control dog died early from an intercurrent infection and four recovered uneventfully. Dogs given mAbs after TBI showed significantly different granulocyte and platelet kinetics. The granulocyte nadir was lower (p = 0.09) and was reached later (p = 0.005), the duration of neutropenia was longer (p = 0.08), and recovery occurred later (p = 0.02) than among controls. Similarly the platelet nadir was lower (p = 0.05), thrombocytopenia lasted longer (p = 0.02), and recovery occurred later (p = 0.02) than among controls. Four of eight mAb-treated dogs died with marrow aplasia. We propose that following irradiation, HLA-DR mediated signals result in terminal differentiation in more mature hematopoietic precursors but interfere with replication or differentiation in early hematopoietic precursors. These observations suggest a role for MHC class II molecules in the regulation of stress hematopoiesis.
authors.affiliation: Program in Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
authors.forename: H J
authors.initials: HJ
authors.lastname: Deeg
authors.forename: K
authors.initials: K
authors.lastname: Seidel
authors.forename: C
authors.initials: C
authors.lastname: Yu
authors.forename: R
authors.initials: R
authors.lastname: Nash
authors.forename: R
authors.initials: R
authors.lastname: Huss
authors.forename: F
authors.initials: F
authors.lastname: Schuening
authors.forename: R
authors.initials: R
authors.lastname: Storb
mesh_terms: D000818:Animals; D000906:Antibodies / Q000494:pharmacology*; D001772:Blood Cell Count; D004285:Dogs; D006684:HLA-DR Antigens / Q000276:immunology*; D006410:Hematopoiesis / Q000187:drug effects / Q000276:immunology / Q000528:radiation effects
chemical_list: D000906:Antibodies; D006684:HLA-DR Antigens